The board of directors of Lijun International Pharmaceutical (Holding) Co. Ltd. announced that the group is expected to record a significant net profit for the year ended 31 December 2012 as compared to a net loss recorded in the year of 2011. This significant net profit is primarily attributable to (i) significant growth of the intravenous infusion solution business of the group in the year of 2012 and (ii) no impairment loss being required to be recognized on goodwill for the year ended 31 December 2012 in respect of the intravenous infusion solution business of the group based on preliminary information received by the Board on 25 February 2013 on the valuation of the Shijiazhuang No.

4 Pharmaceutical Co. Ltd. This is in contrast with a recognition of goodwill impairment loss for the year of 2011 based on a valuation report received by the board on 23 February 2012 on the valuation of the Shijiazhuang No. 4 Pharma and as announced by the company on the same date.